Search 

Wuxi High-tech zone is focusing on developing biopharmaceutical industry. It is one of the top high-tech zones in China. There are a number of famous biopharmaceutical companies such as AstraZeneca, Wuxi AppTech.

Located at the High-Tech center, Silicon Valley, ZJ Future was established in 2013 as a bridge between China and the US to offer accelerating services for domestic enterprises with global perspectives. ​



With the vision of accelerating enterprise development and growth, we leverage the complementary advantages of North America, Europe, South America, and the Asia-Pacific regions to connect high-quality projects with industry leaders, promote academic communications and interactions in high-tech fields, aggregate global entrepreneurial and innovative resources, build an effective and efficient global innovation ecosystem, and develop high-level and multi-field cooperation in the fields of economy, trade, investment, science, and technology.

ZY Therapeutics Inc. is a venture backed startup company focusing on developing innovative precision drug delivery technology. It was founded by two scientists in 2015 in North Carolina. In 2017, ZY’s leading project won collaboration award from Nanotechnology Characterization Lab (NCL), part of national lab established by FDA, NCI and NIST in a concerted effort to regulate and support nanotechnology in oncology space. ZY’s proprietary delivery platforms currently focus on optimized injectable formulations to deliver oncology therapy to the action sites. The first biodegradable oncology nano-formulation, ZY-010-PNP, completed Pre-IND discussion with the FDA and agreement on 505b(2) regulatory pathway was achieved. Further, the isotope labeling human plasma In vitro study as well as canine pharmacokinetic study conducted by NCL suggest a unique drug releasing profile in comparison to the benchmark brands suggesting enhanced the therapeutic effect with lower safety concern. The active targeting delivery nanomedicine ZY-012-CNP for prostate cancer is in preclinic development and scheduled to file Pre-IND application in 2021. Additional products are in encapsulation feasibility studies including targeting dry eye disease and other solid tumors. The target indications cover majority of solid tumors, including but not limited to TNBC, Ovarian Cancer and mCPRC, of which xenograft in vivo models have proved the drug efficacy.
ZY has developed multiple platform technologies and related patents were filed to protect global rights. The key platform patent was awarded by USPTO in 2019. Additional patents on individual product will be filed to protect the exclusive rights. This layered IP strategy ensures a long patent life for future product.
Located in Research Triangle Park in North Carolina, ZY Therapeutics has an interdisciplinary R&D team and 4,500+ sf lab space right in the heart of the southeast bio-hub. Co-founder and CEO Dr. Jian Bao has 18 years’ experience in pharmaceutical development, from discovery to clinical development. She received PhD from University of Pittsburgh and B.S. from Beijing University, both in Chemistry. The core team has a combined decades of pharmaceutical product development experience, with veteran cross-functional team leaders. ZY has assembled an advisor board that consists of world class experts in drug delivery and oncologists from both academia and industry.
ZY Therapeutics is actively seeking funding and collaboration to further develop our platform technologies and promising candidates. We look forward to taking our nano-formulations to clinic in 2021 and beyond.

The project focuses on the research and development of anti-tumor photosensitizing drugs for photodynamic therapy, creating a research and development technology platform for photosensitizing drugs, and conducting clinical development and transformation of anti-tumor photosensitizing drugs. The new anti-tumor photosensitizer drugs developed by our team exhibited excellent tumor enrichment and high efficacy of photodynamic therapy. They have great potential for clinical development and application.

成都新华海纳医疗创新股权投资中心（有限合伙）该支基金由新华瑞恒基金管理公司与雷宁博士等医疗领域专业投资团队共同发起。基金围绕创新医药、医疗器械、医疗服务领域中临床应用前景良好,市场空间巨大的早期企业,以及未来5年营业收入及净利润增长迅速,可能成为龙头企业或并购标的。其中,创新医药以早期大、小分子创新药物和海外引进创新药物为主要布局方向；医疗器械以天使轮/A轮微创外科和生物材料为重点关注对象；医疗服务领域将以高性能生物材料研发平台、医疗互联网平台和医疗人工智能平台为主。

荷兰驻华大使馆。
协助荷兰企业对接中国合作伙伴。